-

VectorBuilder Wins BioIndustrial Innovation of the Year Award

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition underscores VectorBuilder’s significant contributions to gene delivery technology through its Vector Design Studio, which has revolutionized the way researchers worldwide create and order custom gene delivery vectors.

Now in its fourth year, the annual BioTech Breakthrough Awards recognize the world’s best life sciences and biotechnology companies, products, and services. VectorBuilder’s platform was selected for its efficiency, user-friendliness, and ability to accelerate research timelines. The Vector Design Studio has become an indispensable tool for over 300,000 life sciences labs globally, meeting the demand for a faster, more reliable vector design and construction solution.

“Winning this reward reflects our continued commitment to accelerating the pace of gene therapy research through advanced technologies and custom-built solutions transforming how diseases are treated,” said Bruce Lahn, Chief Scientist at VectorBuilder. “Our platform’s ability to reduce vector creation timelines from months to just a few weeks allows researchers to focus on what truly matters: advancing knowledge and developing innovative research and therapies.”

Traditionally, labs have relied on in-house cloning for vector creation, a process that can be slow, costly, and inconsistent. VectorBuilder’s Vector Design Studio changes this by offering an intuitive, Web-based platform that allows even novice researchers to design and order custom vectors with just a few clicks. The platform includes access to an extensive library of over 1,100 vector backbones and more than 400,000 vector components, providing tailored vector solutions with unmatched speed and precision.

The platform has achieved widespread success and adoption. To this end, it’s been used to design over one million vectors that have been cited in more than 5,000 publications, including journals like ‘Science,’ ‘Nature,’ and ‘Cell.’

“The Vector Design Studio merges cutting-edge information technology with synthetic and molecular biology to provide a scalable solution for labs of all sizes,” said Lahn. “By automating the process from demand analysis to vector optimization and delivery, we offer a cost-effective model that helps labs accelerate their research timelines and lower labor expenses. This award inspires us to continue pushing the boundaries of what’s possible in gene delivery.”

Beyond its technical innovation, VectorBuilder’s platform also delivers a significant financial impact. With more than 80% of custom vectors made from ready-made elements, VectorBuilder’s streamlined approach allows for large-scale production, enabling labs to complete projects faster and more affordably. The Vector Design Studio has pioneered a new era of large-scale gene vector production, which has the potential to accelerate life sciences research by up to 20%, according to leading investment firm Legend Capital.

VectorBuilder is a global CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) providing comprehensive, end-to-end gene delivery solutions, including custom vector design, plasmid production, and viral vector manufacturing. With a strong foundation in GMP manufacturing, VectorBuilder has earned the trust of over 4,500 academic institutions and biotech/pharmaceutical companies worldwide.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.

Contacts

More News From VectorBuilder

VectorBuilder Redefines Plasmid Standards with miniVec

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv. Plasmids have long been a key material in the manufacturing of biopharmaceuticals, especially genetic medicines such as viral and non-viral vectors used in gene and cel...

VectorBuilder Wins Two IMAPAC Awards, Cementing Leadership in Gene Therapy and CDMO Innovation

CHICAGO--(BUSINESS WIRE)--VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 (APCGTEA) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 (APBCEA), hosted by IMAPAC. Best Cell & Gene Therapy Supplier Award – AAV Vector Manufacturing Best Gene Therapy CDMO – Asia-Pacific VectorBuilder pioneers cutting-edge innovation for AAV gene delivery, with a one-stop solution supporting progra...

VectorBuilder Powers FDA IND Approval of World’s First Umbilical Cord Blood-Derived Allogeneic CAR-T Product

CHICAGO--(BUSINESS WIRE)--VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) on January 11, 2025. VectorBuilder has provided highly customized end-to-end CDMO solutions to support this clinical pipeline. Dr. Bruce Lahn, Chief Scientist at VectorBuilder, commented, "Congratulations to Chengdu Ucello on the FDA IND app...
Back to Newsroom